Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC

(MedPage Today) -- The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on Wednesday. The approval was...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news